Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2024-05-17 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
2023年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled as "2023 年年度股东大会会议资料" which translates to "2023 Annual General Meeting (AGM) Meeting Materials". It contains detailed information about the AGM including meeting notices, agenda, proposals to be voted on, and reports to be presented at the AGM. The content includes instructions for shareholders, meeting procedures, voting details, and summaries of reports such as the annual report, financial statements, profit distribution, and board reports, all typical of AGM materials. The document is not the annual report itself but the materials prepared for the AGM where such reports are discussed and approved. Therefore, this document fits the category of AGM Information (AGM-R).
2024-05-17 Chinese
海通证券股份有限公司关于上海宣泰医药科技股份有限公司2023年度持续督导年度跟踪报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度持续督导年度跟踪报告" which translates to "2023 Annual Continuous Supervision Follow-up Report" by the sponsoring securities company for a listed company. It details the continuous supervision activities conducted by the sponsor during the year 2023, including compliance checks, governance, internal controls, information disclosure reviews, and other regulatory oversight tasks. The document references regulatory approvals, ongoing monitoring, and reporting obligations under securities laws and stock exchange rules. It is a detailed report on the sponsor's supervision work rather than a general annual report, earnings release, or other financial statement. This type of document is typically classified as an Audit Report / Information (AR) because it relates to regulatory compliance, audit, and supervisory activities rather than the company's own financial results or management commentary. The document length is substantial (15,000 characters), and it contains substantive content rather than just an announcement or certification. Therefore, the best fitting category is AR (Audit Report / Information).
2024-05-13 Chinese
海通证券股份有限公司关于上海宣泰医药科技股份有限公司2023年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "现场检查报告" (on-site inspection report) by the sponsor (Haitong Securities) regarding the continuous supervision of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. for the year 2023. It references regulatory approvals, continuous supervision period, and detailed findings on governance, internal controls, information disclosure, independence, use of raised funds, related party transactions, and operational status. The document is a detailed report of the sponsor's on-site inspection and continuous supervision activities, not a full annual report or audit report. It is a specific regulatory compliance and supervision report related to the continuous supervision obligations of the sponsor under Chinese securities regulations. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. The document is not an announcement or a brief notice but a substantive report. The length (3184 characters) is relatively short but contains detailed findings and opinions, consistent with an audit or inspection report rather than a mere announcement or certification. Therefore, the classification is AR with high confidence.
2024-05-13 Chinese
关于股份回购进展公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with relevant regulations. The document does not contain financial statements or detailed financial analysis but focuses on the update of the company's share buyback activity. The length is 1573 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2024-05-05 Chinese
关于参加2023年度科创板制药专场集体业绩说明会暨2023年第一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the company's participation in an investor performance briefing session for the 2023 annual and 2024 first quarter results. It mentions that the company has already published the 2023 annual report and 2024 Q1 report on April 30, 2024, and this announcement is about the upcoming interactive session to discuss those results. The document is short (1380 characters) and serves as a notice for the event rather than containing the actual financial data or detailed report. Therefore, it fits the category of an Investor Presentation (IP) announcement or an invitation to a performance briefing rather than the report itself. Given the detailed description of the event and interaction with investors, the best classification is Investor Presentation (IP).
2024-05-05 Chinese
募集资金管理制度（2024年4月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '募集资金管理制度' (Fundraising Capital Management System) for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It outlines the management, storage, usage, supervision, and change procedures related to the company's raised funds. The content is regulatory and procedural in nature, focusing on compliance with laws and internal governance regarding fundraising capital. It does not contain financial statements, earnings data, or audit results. It is not an announcement or a brief summary but a comprehensive governance document about fundraising capital management. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2024-04-29 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.